Kralovics, R., et al. (2002). Acquired uniparental disomy of chromosome 9p is a frequent stem cell defect in polycythemia vera. Experimental Hematology, 30(3), 229–236.

Klampfl, T., et al. (2013). Somatic mutations of calreticulin in myeloproliferative neoplasms. The New England Journal of Medicine, 369(25), 2379–2390.

Moliterno, A. R., et al. (2006). Molecular mimicry in the chronic myeloproliferative disorders: Reciprocity between quantitative JAK2 V617F and MPL expression. Blood, 108(12), 3913–3915.

Rampal, R., et al. (2014). Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis. Blood, 123(22), e123-133. https://doi.org/10.1182/blood-2014-02-554634

Tefferi, A., et al. (2006). International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). Blood, 108(5), 1497–1503.

Ishii, T., et al. (2006). Involvement of various hematopoietic-cell lineages by the JAK2V617F mutation in polycythemia vera. Blood, 108(9), 3128–3134.

Kilpivaara, O., et al. (2009). A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms. Nature Genetics, 41(4), 455–459.

Gleitz, H. F. E., et al. (2020). Increased CXCL4 expression in hematopoietic cells links inflammation and progression of bone marrow fibrosis in MPN. Blood, 136(18), 2051–2064.

Egeren, D. V., et al. (2022). Transcriptional differences between JAK2-V617F and wild-type bone marrow cells in patients with myeloproliferative neoplasms. Experimental Hematology, 107, 14–19.

Cimen Bozkus, C., et al. (2019). Immune Checkpoint Blockade Enhances Shared Neoantigen-Induced T-cell Immunity Directed against Mutated Calreticulin in Myeloproliferative Neoplasms. Cancer Discovery, 9(9), 1192–1207.